An interventional study of Non-invasive Temporal Interference (TI) Stimulation Targeting Bilateral Hippocampi in Temporal Lobe Epilepsy (TLE), Drug Resistant Epilepsy and Sleep, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Duke University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Epilepsy, Temporal Lobe with a site in United States — 10 open to participants now, 10 under way, none of them phase 3. Epilepsy, Temporal Lobe · United States.
Among the 30 studies in Epilepsy, Temporal Lobe with a site in United States, this one is the 7th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2026, is one of 11 with no phase, and was the 29th registered.
65 studies on the registry are indexed under Epilepsy, Temporal Lobe; 25 are open to participants now.
Browse Epilepsy, Temporal Lobe studies →10 of the 30 studies in Epilepsy, Temporal Lobe with a site in United States are open now. Recruiting first, the newest first:
Neurona Therapeutics · Sites in United States
Ages 18–75
University of California, Davis · Sites in United States
Ages 18–55 · Healthy volunteers
Nitin Tandon · Sites in United States
Ages 18–65
University of Southern California · Sites in United States
Ages 18–65
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Epilepsy, Temporal Lobe studies recruiting now, 6 (32%) set no upper age limit and 9 (47%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 1 · Phase 4 2
First in 1997; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 30 across 41 interventional studies indexed under Epilepsy, Temporal Lobe.
Median enrollment 10 across the 19 interventional studies, 50 across the 11 observational. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 30 have an industry lead sponsor. The 10 most frequent:
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
Duke University has 2 studies filed under Epilepsy, Temporal Lobe — fewer than ten, so there is no comparison to draw.
3 of the studies in Epilepsy, Temporal Lobe with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02151175BrainSonix Inc.Low-intensity Focused Ultrasound Pulsation (LIFUP) for Treatment of Temporal Lobe Epilepsy | 2026-11 |
| NCT04649008University of PennsylvaniaLocalizing Epileptic Networks Using MRI and iEEG | 2027-02-28 |
| NCT06422923Neurona TherapeuticsA Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) | 2027-06-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Epilepsy, Temporal Lobe with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to gauge whether overnight, non-invasive temporal interference (TI) stimulation aimed at the hippocampus can reduce abnormal brain activity linked to seizures and improve sleep in adults with drug-resistant temporal lobe epilepsy. The main questions are:
Does overnight TI stimulation lower seizure-related EEG activity during sleep?
Does overnight TI stimulation improve sleep quality and sleep patterns measured overnight in the lab?
Researchers will compare each participant's nights without stimulation to nights with active stimulation, and will also look at a night after stimulation ends to see whether any changes last.
Participants will:
Stay in-lab for six days for overnight sleep and EEG monitoring
Have one night of monitoring without stimulation
Receive TI stimulation during sleep for several nights
Have another night of monitoring without stimulation after the stimulation nights
Complete brief questionnaires and thinking/memory tasks before and after the stimulation nights
Be checked for side effects and comfort during the study and at follow-up
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Single-group, within-subject protocol with in-laboratory overnight PSG and scalp EEG. Participants complete one baseline night with no stimulation, followed by three consecutive nights of active overnight temporal interference (TI) stimulation targeting bilateral hippocampi, then one post-treatment night with no stimulation to assess persistence. Evening and morning EEG biomarker recordings are collected throughout, with safety/tolerability monitoring and pre/post cognitive and mood assessments.
Device: Non-invasive Temporal Interference (TI) Stimulation Targeting Bilateral Hippocampi
Non-invasive temporal interference (TI) electrical stimulation delivered overnight to target the bilateral hippocampi during in-laboratory polysomnography and scalp EEG monitoring. Stimulation is applied via a multi-channel, current-controlled stimulator using a scalp electrode montage planned with MRI-guided modeling. TI is delivered continuously from lights-off to lights-on for three consecutive nights, with gradual ramp-up and ramp-down at the start and end of each session. Stimulation parameters use kilohertz carrier currents arranged to produce an amplitude-modulated envelope at 130 Hz at each hippocampal target, with current adjusted within preset safety limits based on tolerability and impedance.
Change in Overnight Interictal Epileptiform Discharge (IED) Rate on Scalp EEG
Overnight interictal epileptiform discharge (IED) rate (spikes per minute) computed from scalp EEG during sleep. IEDs will be identified using a standardized scoring pipeline, and the rate will be calculated as total IED count divided by total minutes of sleep (PSG-defined sleep time). Lower values indicate fewer epileptiform discharges (improvement). The primary comparison is baseline no-stimulation night versus the average of the active TI stimulation nights.
Time frame: Baseline (Night 1, no stimulation) and during active TI stimulation nights (average of Nights 2-4, overnight sleep period).
PSG sleep outcomes - time in REM (rapid eye movement)
Overnight polysomnography (PSG) measures of sleep stages and sleep quality/continuity. Higher sleep efficiency and lower fragmentation indicate improvement.
Time frame: Night 1 (no stimulation), Nights 2-4 (active TI), and Night 5 (no stimulation), assessed over each overnight sleep period.
PSG sleep outcomes - efficiency
Overnight polysomnography (PSG) measures of sleep stages and sleep quality/continuity. Higher sleep efficiency and lower fragmentation indicate improvement.
Time frame: Night 1 (no stimulation), Nights 2-4 (active TI), and Night 5 (no stimulation), assessed over each overnight sleep period.
PSG sleep outcomes - wake after sleep onset
Overnight polysomnography (PSG) measures of sleep stages and sleep quality/continuity. Higher sleep efficiency and lower fragmentation indicate improvement.
Time frame: Night 1 (no stimulation), Nights 2-4 (active TI), and Night 5 (no stimulation), assessed over each overnight sleep period.
PSG sleep outcomes - arousal index
Overnight polysomnography (PSG) measures of sleep stages and sleep quality/continuity. Higher sleep efficiency and lower fragmentation indicate improvement.
Time frame: Night 1 (no stimulation), Nights 2-4 (active TI), and Night 5 (no stimulation), assessed over each overnight sleep period.
Morning and evening scalp EEG biomarker burden
Standardized scalp EEG recordings collected twice daily to quantify seizure-related biomarker burden (e.g., IED rate) and track day-to-day changes during the monitoring week. Lower biomarker burden indicates improvement.
Time frame: Evening (~20:00) and morning (~10:00) assessments across the in-lab week (Days 1-6)
Persistence of biomarker changes after stimulation ends - Post treatment night
Biomarker burden on the post-treatment no-stimulation night to assess whether overnight TI effects carry over after stimulation stops, compared with baseline and stimulation nights. Lower biomarker burden indicates improvement
Time frame: Night 5 (no stimulation; overnight sleep period), compared with Night 1 and the average of Nights 2-4
Cognitive performance - Rey/Taylor Figure-copy and immediate recall
Scores on Rey/Taylor Figure copy and immediate recall to assess short-term changes in visuospatial construction and memory before versus after the stimulation block. Higher scores indicate better performance
Time frame: Pre-stimulation (baseline, prior to Night 2) and post-stimulation (after Night 4 or on Day 6)
Psychiatric symptom measures - Beck Anxiety Inventory (BAI)
Scores on validated anxiety and depression scales to assess changes in symptoms before versus after the stimulation block. Lower scores indicate fewer symptoms.
Time frame: Pre-stimulation (baseline, prior to Night 2) and post-stimulation (after Night 4 or on Day 6)
Psychiatric symptom measures - Hamilton Anxiety Rating Scale (HAM-A)
Scores on validated anxiety and depression scales to assess changes in symptoms before versus after the stimulation block. Lower scores indicate fewer symptoms.
Time frame: Pre-stimulation (baseline, prior to Night 2) and post-stimulation (after Night 4 or on Day 6)
Psychiatric symptom measures - Hamilton Depression Rating Scale (HAM-D)
Scores on validated anxiety and depression scales to assess changes in symptoms before versus after the stimulation block. Lower scores indicate fewer symptoms.
Time frame: Pre-stimulation (baseline, prior to Night 2) and post-stimulation (after Night 4 or on Day 6)
Safety and tolerability - adverse events, skin checks, discomfort
Frequency, type, and severity of device- and study-related adverse events (e.g., skin irritation, headache, dizziness, sleep disturbance), plus tolerability/comfort checks during the admission and at follow-up
Time frame: During in-lab monitoring (Nights 1-5) and follow-up (Day 7)
Plan to share: No
Start is estimated for Oct 2026; primary completion for Oct 2026, 0 months later.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.